Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Asahi Kasei $1.1 billion offer to acquire Calliditas Therapeutics
We are advising Lazard as financial adviser to Calliditas on the transaction
Nordson $800 million acquisition of Atrion
We are advising Nordson on the acquisition
AC Immune exclusive option and license agreement with Takeda Pharmaceuticals
We advised AC Immune on the transaction
RxSight $115 million follow-on offering
The stock is listed on the Nasdaq Global Market
Oculis Holding $100 million at-the-market offering
The shares are listed on the Nasdaq Global Market and the Nasdaq Iceland Main Market
ADC Therapeutics $105 million follow-on offering
We advised ADC Therapeutics on its offering of shares and pre-funded warrants
Korro Bio $70 million private placement
The PIPE consists of common stock
TScan Therapeutics $150 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Market
EyeCare Partners new refinancing transaction
We advised the superpriority, first-lien and second-lien administrative agent and the fronting bank on the transaction
Intra-Cellular Therapies $500 million stock offering
The shares are listed on the Nasdaq Global Select Market